@article{ad959ff52e43492bb5f1501c414f171b,
title = "Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology",
abstract = "The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.",
author = "Bristow, {Robert G.} and Brian Alexander and Michael Baumann and Bratman, {Scott V.} and Brown, {J. Martin} and Kevin Camphausen and Peter Choyke and Deborah Citrin and Contessa, {Joseph N.} and Adam Dicker and Kirsch, {David G.} and Mechthild Krause and Le, {Quynh Thu} and Michael Milosevic and Morris, {Zachary S.} and Sarkaria, {Jann N.} and Sondel, {Paul M.} and Tran, {Phuoc T.} and Wilson, {George D.} and Henning Willers and Wong, {Rebecca K.S.} and Harari, {Paul M.}",
note = "Funding Information: Before initiation of this paper, all members of the American Society for Radiation Oncology (ASTRO) White Paper Task Group were required to complete disclosure statement, which are maintained at the ASTRO Headquarters in Arlington, VA, USA, and disclosed herein. BA is a consultant for Abbvie. MB is a member of the Scientific Advisory Board for Merck & Co. AD is a consultant for Glenview, a health-care consulting firm. DGK is a consultant for Lumicell Diagnostics and owns stock in Lumicell Diagnostics and XRAD Therapeutics. He has also received research funding from Janssen and Merck for a phase 2 trial. MK receives research funding from Merck. Q-TL owns stock in ALDEA Pharmaceuticals and receives research funding from Amgen. JNS receives research funding from Eli Lily and Genentech. PTT holds patents for compounds and methods of use in ablative radiation therapy. All other authors declare no competing interests. The chairs of this White Paper panel and the Chairs of the Science Council reviewed these disclosures and determined that they did not present a conflict with respect to these panel members' work on this guideline. Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",
year = "2018",
month = may,
doi = "10.1016/S1470-2045(18)30096-2",
language = "English (US)",
volume = "19",
pages = "e240--e251",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",
}